Commentary|Videos|November 18, 2026

Alternating Pazopanib and Bevacizumab Shows Promise in Metastatic ccRCC

Fact checked by: Matt Flowers

Dr Saby George discusses the biological rationale for alternating pazopanib and bevacizumab in metastatic clear cell renal cell carcinoma.

Alternating 2 VEGF-targeted therapies may offer an approach to addressing treatment resistance in metastatic clear cell renal cell carcinoma (ccRCC), according to Saby George, MD, FACP, of Roswell Park Comprehensive Cancer Center.

In an interview with Targeted OncTM, George explains the biological rationale behind investigating pazopanib (Votrient), a VEGFR-targeted tyrosine kinase inhibitor (TKI), and bevacizumab (Avastin), a VEGF-directed monoclonal antibody. Evidence suggests that treatment with VEGFR-targeted TKIs can increase circulating VEGF ligand levels, potentially contributing to treatment resistance.

Although pazopanib inhibits VEGFR signaling, increased VEGF ligand production may provide a mechanism through which tumors overcome this inhibition. Bevacizumab addresses this potential resistance mechanism through a complementary approach by binding circulating VEGF ligands and preventing them from interacting with VEGF receptors.

Previous studies investigated combining VEGF-targeted TKIs with bevacizumab to achieve this complementary effect. However, these combinations proved too toxic. To address this challenge, investigators developed an alternating treatment schedule designed to maintain VEGF pathway inhibition while avoiding the toxicity associated with concurrent administration.

The phase 1/2 study, published in The Lancet Oncology, evaluated pazopanib 800 mg daily on days 1 through 28, followed by bevacizumab 10 mg/kg on days 36 and 50 of each 10-week cycle. In the phase 2 efficacy population of 51 patients with previously untreated metastatic ccRCC, median progression-free survival (PFS) was 24.8 months, and median overall survival (OS) was 63.2 months after a median follow-up of 63.7 months. The most common grade 3 or 4 treatment-related adverse events were hypertension (34%) and elevated alanine aminotransferase (17%).1

George explains that the initial objective was to establish a safe alternating regimen suitable for further clinical investigation. The findings demonstrated promising antitumor activity, particularly in a population predominantly comprising patients with favorable-risk disease. However, the single-arm study design means randomized phase 3 data are needed to confirm the findings and establish the regimen's role in the treatment landscape.

REFERENCE
1. George S, Vaishampayan U, Hutson A, et al. Pazopanib alternating with bevacizumab in patients with metastatic clear-cell renal cell carcinoma naive to treatment: a multicentre, single-arm, phase 1/2 trial. Lancet Oncol. 2026. doi:10.1016/S1470-2045(26)00394-3.

Related to this article